Similar to the role of mutations in BRCA1/2 in the development of breast cancer and ovarian cancer [14], various studies have shown that inactivating BRCA1/2 mutations, predominantly BRCA2, increase predisposition to PCa (Table 1) [7–9, 27–29]. The gene discussed is BRCA1; the disease is ovarian cancer.